ASX ANNOUNCEMENTS

Announcement Title: Pharmacy Catalyst Members In-Pharmacy Asthma Mgt Program 8 February 2021
Announcement Title: Change of Director’s Interest Notice – TD 2 February 2021
Announcement Title: Change of Director’s Interest Notice – MM 2 February 2021
Announcement Title: Change of Director’s Interest Notice – NS 2 February 2021
Announcement Title: Appendix 4C – quarterly 27 January 2021
Announcement Title: Appendix 2A – exercise of options 18 January 2021
Announcement Title: SuperChem to Commence Sales of wheezo 14 January 2021
Announcement Title: Appendix 3G 29 December 2020
Announcement Title: Proposed issue of Securities – RSH 23 December 2020
Announcement Title: Results of Annual General Meeting 16 December 2020
Announcement Title: CEO’s Update at AGM 16 December 2020
Announcement Title: Change of Director’s Interest Notice – MM 16 December 2020
Announcement Title: Change of Director’s Interest Notice – NS 16 December 2020
Announcement Title: New Partnership with Pharmacy 4 Less Banner Group 16 December 2020
Announcement Title: Company Update Post Commercial Launch 9 December 2020
Announcement Title: Michael Clarke Ambassador & Carlton AFLW co-sponsor 4 December 2020
Announcement Title: Appendix 2 25 November 2020
Announcement Title: Notice of Annual General Meeting 12 November 2020
Announcement Title: Manufacturing update 4 November 2020
Announcement Title: wheezo Launch Update 30 October 2020
Announcement Title: Patent application filed – Next Generation wheezo algorithm 29 October 2020
Announcement Title: Appendix 2A 28 October 2020
Announcement Title: Amended – Change in substantial holding 23 October 2020
Announcement Title: Change in substantial holding 23 October 2020
Announcement Title: Appendix 4C – quarterly 22 October 2020
Announcement Title: Cipla launches wheezo sales and marketing activity 21 October 2020
Announcement Title: Cleansing Prospectus 20 October 2020
Announcement Title: Placement investor presentation 20 October 2020
Announcement Title: Proposed issue of Securities – RSH 20 October 2020
Announcement Title: $12.5m Placement Completed 20 October 2020
Announcement Title: Trading Halt 14 October 2020
Announcement Title: Annual Report – Corporate Governance Statement 02 October 2020
Announcement Title: Annual Report to shareholders 29 September 2020
Announcement Title: Appendix 4G – Corporate Governance Statement 29 September 2020
Announcement Title: Copy of update given 24 September 2020
Announcement Title: Respiri to provide shareholder update via Zoom 23 September 2020
Announcement Title: Entech Electronics appointed as Global Manufacturing Partner 22 September 2020
Announcement Title: Positive wheezo clinical study results 1 September 2020
Announcement Title: Respiri Partners with Carlton Football Club AFLW Team 27 August 2020
Announcement Title: Preliminary Final Report 27 August 2020
Announcement Title: Product Referral Agreement executed with Aust Patients Assoc 19 August 2020
Announcement Title: Australian Patients Association partnership 12 August 2020
Announcement Title: Manufacturing update 7 August 2020
Announcement Title: CY21 Revenue Guidance 27 July 2020
Announcement Title: Share sale facility for less than marketable parcels closes 24 July 2020
Announcement Title: Appendix 4C – quarterly 22 July 2020
Announcement Title: Respiri signs with BNPL provider ZIP – update 20 July 2020
Announcement Title: Respiri signs with BNPL provider ZIP 20 July 2020
Confirmation of Release – RSH – Update – Proposed issue of Securities 17 July 2020
Announcement Title: Appendix 3G 17 July 2020
Confirmation of Release – RSH – Exclusive International Sales Agreement with Cipla 17 July 2020
Announcement Title: Trading Halt 15 July 2020
Announcement Title: Proposed issue of Securities – RSH 29 June 2020
Announcement Title: Agreement with UK Data Research Centre executed 26 June 2020
Announcement Title: Appendix 2A 19 June 2020
Announcement Title: Settlement with former CEO 18 June 2020
Announcement Title: Change of Director’s Interest Notice MM 17 June 2020
Announcement Title: Change of Directors Interest Notice TD 17 June 2020
Announcement Title: Change of Director’s Interest Notice NS 17 June 2020
Announcement Title: Service Agreement with Pharmacy Guild of Australia 16 June 2020
Announcement Title: Proposed issue of Securities – RSH 16 June 2020
Announcement Title: Confirmation of Release – RSH – Details of Company Address 15 June 2020
Announcement Title: Proposed Issue of Securities 15 June 2020
Announcement Title: Proposed Issue of Securities 15 June 2020
Announcement Title: Application for quotation of +securities 11 June 2020
Announcement Title: Proposed Issue of Securities 10 June 2020
Announcement Title: Share Trading Policy – updated 5 June 2020
Announcement Title: Application for quotation of +securities 3 June 2020
Announcement Title: Share sale facility for holders of less than marketable parcels 2 June 2020
Announcement Title: Proposed Issue of Securities 1 June 2020
Announcement Title: Results of Extraordinary General Meeting (EGM) 26 May 2020
Announcement Title: CEO’s Address to Shareholders 25 May 2020
Announcement Title: Appendix Appendix 3B – SPP 6 May 2020
Announcement Title: Appendix 2A – SPP 6 May 2020
Announcement Title: Security Purchase Plan – Completed 6 May 2020
Announcement Title: Security Purchase Plan – Supplementary 5 May 2020
Announcement Title: Virtual conference presentation 4 May 2020
Announcement Title: Respiri to present at virtual health conference 1 May 2020
Announcement Title: AsthmaCare Telehealth Service with Practice Innovators 29 April 2020
Announcement Title: Appendix 4C – quarterly 30 April 2020
Announcement Title: Bi-monthly shareholder update 21 April 2020
Announcement Title: Respiri Limited Shareholder Update 21 April 2020
Announcement Title: Respiri Partners with Phenix Health for wheezo® Telehealth Delivery 14 April 2020
Announcement Title: Share Purchase Plan and Extraordinary General Meeting 9 April 2020
Announcement Title: Security Purchase Plan 9 April 2020
Announcement Title: Respiri Raises $2.0 Million and Announces Additional Share Purchase Plan 26 March 2020
Announcement Title: Placement – investor presentation 17 March 2020
Announcement Title: wheezos in Chinese Hospitals 11 March 2020
Announcement Title: First batch of wheezos delivered 5 March 2020
Announcement Title: Claim by previous CEO 27 February 2020
Announcement Title: Bi-monthly update 25 February 2020
Announcement Title: Update on the new CEO 13 February 2020
Announcement Title: Appointment of director 12 February 2020
Announcement Title: Resignation of director 11 February 2020
Announcement Title: World Class Team Now in Place for 2020 31 January 2020
Announcement Title: FDA application – update 30 January 2020
Announcement Title: Respiri to lodge FDA application in the USA for wheezo 29 January 2020
Announcement Title: Saas company overview 20 January 2020
Announcement Title: Conference call: Strategic Review and Implementation Update 9 January 2020
Announcement Title: SaaS model & First 500 devices 13 December 2019
Announcement Title: CE Mark, manufacturer & clinical study agreement 10 December 2019
Appendix 3B – shares to ex-director following AGM approval 9 December 2019
Announcement Title: Change in substantial holding (prior year) 5 December 2019
Announcement Title: Change of Director’s Interest Notice 28 November 2019
Announcement Title: Initial Director’s Interest Notice 27 November 2019
Announcement Title: Results of 2019 Annual General Meeting 26 November 2019
Confirmation of Release – RSH – Director Resignation 25 November 2019
Announcement Title: Director and CEO Appointment 25 November 2019
Announcement Title: Change of Chairman 15 November 2019
Confirmation of Release – RSH – App 4G & Corporate Governance Statement 14 November 2019
Announcement Title: Annual Report updated to include shareholder information 13 November 2019
Announcement Title: Initial Director’s Interest Notice 6 November 2019
Announcement Title: Appointment of new director 30 October 2019
Announcement Title: Request to convene general meeting received 30 October 2019
Announcement Title: Update regarding departure of CEO 30 October 2019
Announcement Title: Appendix 4C – quarterly 25 October 2019
Announcement Title: Notice of Annual General Meeting 25 October 2019
Announcement Title: CEO leaving 9 October 2019
Announcement Title: Shareholder update – wheezo 9 October 2019
Announcement Title: Medical trial in India update 20 September 2019
Announcement Title: Annual Report to shareholders 17 September 2019
Announcement Title: Dispute with former directors resolved 9 September 2019
Announcement Title: wheezo diary app 4 September 2019
Announcement Title: Preliminary Final Report 28 August 2019
Listen to the Shareholder Update conference call held on 14 August 2019 Speakers: Mario Gattino, CEO, Prof Bruce Thompson, Director, Wani Wall, CXO and Evan Davey, Partner Two Bulls.
Respiri progresses Indian Market Entry 14 August 2019
Announcement Title: Appendix 3B – REVISED 13 August 2019
Announcement Title: Cleansing Notice 9 August 2019
Announcement Title: Notice of upcoming investor update 9 August 2019
Announcement Title: Placement settlement 8 August 2019
Announcement Title: Appendix 3B correction 31 July 2019
Announcement Title: Investor Update 30 July 2019
Announcement Title: Appendix 4C 30 July 2019
Announcement Title: Appendix 3B 30 July 2019
Announcement Title: Placement Term ASX Announcement 2019 30 July 2019
Announcement Title: Suspension from Official Quotation 29 July 2019
Announcement Title: Respiri Limited (ASX: RSH) – Trading Halt 25 July 2019
Announcement Title: Clinical Trial Update 18 June 2019
Announcement Title: Issue of Options to senior management 11 June 2019
Announcement Title: India JV Strategy Update 6 June 2019
Announcement Title: India Joint Venture Agreement 3 May 2019
Announcement Title: Appendix 4C – quarterly 30 April 2019
Announcement Title: WHEEZO CLINICAL STUDY TO COMMENCE 29 April 2019
Announcement Title: Details of Share Registry address 11 April 2019
Listen to the Shareholder Update Conference Call recorded 28 March 2019
Announcement Title: Shareholder teleconference presentation 28 March 2019
Announcement Title: Shareholder conference call 26 March 2019
Announcement Title: Respiri progresses CE Mark registration 22 March 2019
Announcement Title: Company Secretary Appointment/Resignation 14 March 2019
Announcement Title: RESPIRI ANNOUNCES IR APPOINTMENT 13 March 2019
Announcement Title: Appendix 4D and Interim Financial Report (December 2018) 27 February 2019
Announcement Title: Medical Device Path To Market Update 21 February 2019
Announcement Title: Appendix 3B 15 February 2019
Announcement Title: Cleansing Notice – Respiri Limited 11 February 2019
Announcement Title: Appendix 3B 11 February 2019
Announcement Title: Michael Clarke Kits Up For Respiri 7 February 2019
Announcement Title: Completion Of Share Purchase Plan Offer 4 February 2019
Announcement Title: Appendix 4C – quarterly 31 January 2019
Announcement Title: Auditor Change Finalised 17 January 2019
Announcement Title: Wheezo Exhibits at Consumer Electronics Show CES 2019 9 January 2019
Opportunity for shareholders to participate in Respiri share purchase plan 7 January 2019
Announcement Title: Appendix 3B 21 December 2018
Announcement Title: $3.2M Share Placement Settlement 21 December 2018
Confirmation of Release – RSH – $3.2M Share Placement 18 December 2018
Announcement Title: Significant strategic partnership for China distribution 17 December 2018
Announcement Title: Election of Chairman 18 December 2018
Announcement Title: Results of 2018 Annual General Meeting 28 November 2018
Announcement Title: CEO Presentation – Annual General Meeting 28 November 2018
Announcement Title: Final Director Interest Notices 27 November 2018
Announcement Title: CHANGE OF RESPIRI BOARD OF DIRECTORS 27 November 2018
Listen to the Shareholder Conference Call held on Tuesday 13 November featuring a comprehensive operations update from CEO Mario Gattino, Medical & Scientific Advisor, Prof Bruce Thompson and CXO, Wani Wall. 13 November 2018
Announcement Title: Future Milestones Set For The Launch Of Wheez 13 November 2018
Announcement Title: Shareholder Update November 2018
Announcement Title: Shareholder Update October 30, 2018
Announcement Title: Appendix 4C and R&D Incentive Announcement November 9, 2018
Announcement Title: Annual Report to shareholders October 26, 2018
Announcement Title: Appendix 4G and Corporate Governance Statement October 26, 2018
Announcement Title: Notice of Annual General Meeting/Proxy Form October 26, 2018
Announcement Title: New Board Member Appointed October 24, 2018
Product Naming Survey Confirms Market Demand October 19, 2018
CEO’S ‘100 DAY’ UPDATE SEPTEMBER 2018
RESPIRI COMMERCIALISATION STRATEGY GATHERS MOMENTUM September 21, 2018
RESPIRI APPOINTS MANUFACTURING PARTNER September 7, 2018
Director Options Update August 31, 2018
Director Options Update August 10, 2018
Confirmation of Release – RSH – Appendix 4C – Quarterly July 30, 2018
Confirmation of Release – RSH – CEO Operational Review July 30, 2018
Announcement Title: Directors Options July 6, 2018
RSH – APPOINTMENT AND RESIGNATION OF COMPANY SECRETARY July 3, 2018
New Chair appointed 14 June, 2018
Appendix 3Z – Final Director’s Interest Notices 5 June, 2018
Appendix 3X – Initial Director’s Interest Notice 30 May, 2018
RSH – Significant Milestone Progress 30 May, 2018
RSH – Changes to Respiri Board 30 May, 2018
RSH – Appendix 3Y – Change of Director’s Interest Notice 4 May, 2018
RSH – Appendix 3Y – Change of Director’s Interest Notice 1 May, 2018
RSH – Appendix 4C – quarterly 30 April, 2018
Listen to CEO Mario Gattino’s conference call from San Francisco where he is attending “The Digital Medtech Conference” to introduce global innovators and key decision makers to Respiri’s Asthma Management Ecosystem. Listen now
RSH – Respiri Accelerating Activity 24 April, 2018
Respiri Limited – Functional Prototype Completed 20 April, 2018
RSH – Respiri Limited $3.0M Share Placement & Appendix 3B 18 April, 2018
RSH – Respiri Limited – Cleansing Notice 18 April, 2018
RSH – RESPIRI LIMITED $3.0m SHARE PLACEMENT 10 April, 2018
CEO’s 100 Day Update 5 March, 2018
RSH – Half Year Announcement – February 2018 26 February, 2018
Appendix 4D and Interim Financial Report – December 2017 26 February, 2018
CEO Update and Reaffirmation of 2018 Plans and Milestone 29 January, 2018
RSH – Appendix 4C – quarterly 29 January, 2018
Appendix 3X – Initial Director’s Interest Notice 21 December, 2017
Appendix 3X – Initial Director’s Interest Notice 21 December, 2017
Appendix 3Y – Change of Director’s Interest Notices (x2) 21 December, 2017
Appendix 3Z – Final Director’s Interest Notice 21 December, 2017
Confirmation of Release – RSH – Appendix 3B 20 December, 2017
RESULTS OF ANNUAL GENERAL MEETING Dec 15, 2017
2017 AGM – Chairman’s Address Dec 14, 2017
AGM – Change of Venue & Start Time Nov 29, 2017
2017 Notice of Annual General Meeting and Proxy Form Nov 14, 2017
AirSonea Generation 2 Breath Sensor Update Oct 30, 2017
Appendix 4C – quarterly Oct 30, 2017
Extension of Date for Annual General Meeting Oct 26, 2017
RSH – Respiri Receives Notice of Intention Oct 17, 2017
ASX Announcement – Respiri appoints new CEO 16 October, 2017
RESPIRI FEATURED IN SMALL CAPS NEWS WEBSITE Respiri is starting to catch the attention of investors and the media as it closes in on the launch of its first commercial product. Market news and information site, Small Caps, has featured the company and has interviewed chairman, Leon L’Huillier, about what lies ahead for the company. Click here to read the article.
Alan Kohler speaks with Chairman, Leon L’Huillier about the opportunity for Respiri and its shareholders as it works through the final steps to commercialisation. Click on the link to hear the podcast and see more great stories from Alan Kohler, The Constant Investor. Listen now
Breath Sensor Partnership with Grey Innovation Commenced September 12, 2017
Appendix 4E & Annual Financial Report (30 June 2017) August 30, 2017
Respiri remains on track for commercialisation August 9, 2017
Commencing the last step to commercialisation July 27, 2017
Appendix 4C – quarterly July 27, 2017
Respiri & ChinaMay 30, 2017
Company Secretary Appointment/ResignationMay 17, 2017
Executive Chair Remuneration Update May 17, 2017
Appendix 4C – QuarterlyApril 27, 2017
Partner Discussions Encouraging April 27, 2017
European CE Mark Approval Received Paving the Way for Successful Partnership Discussions April 12, 2017
Appendix 3B March 1, 2017
Text and App Messaging for Better Asthma Care February 28, 2017
Appendix 3B February 28, 2017
Appendix 3B February 27, 2017
Respiri Appendix 4D and Interim Financial Report – Dec 2016 February 28, 2017
RSH – Corporate Advisor for Partner Transactions February 9, 2017
RSH – Dec 16 Appendix 4C – Respiri January 31, 2017
RSH – RESPIRI COMPLETES CORE SOFTWARE PLATFORM January 31, 2017
Appendix 3B – Issue of Capital from AGM Resolutions December 20, 2016
Appendix 3Y – Change of Director’s Interest Notices (x3) December 20, 2016
Overnight Monitoring Product Accelerated December 15, 2016
RSH – Results of Respiri 2016 Annual General Meeting November 22, 2016
RSH – Chairman’s Address to Shareholders November 22, 2016
Respiri Market Update – November 2016 November 15, 2016
UK Offers Scope for Respiri to Develop Key Partnerships November 9, 2016
Appendix 3Z – Final Director’s Interest Notices (DH & RBH) October 26, 2016
Appendix 4C – First Quarter Cash Report – FY2017 October 26, 2016
RSH – Notice of Annual General Meeting/Proxy Form October 21, 2016
RSH – ANNUAL FINANCIAL REPORT June 30, 2016
Appendix 4G – Corporate Governance Disclosure Document August 31, 2016
Respiri’s Continued Leadership in Asthma Monitoring August 31, 2016
Appendix 4C – 4th Quarter: Quarterly report for entities admitted on the basis of commitments July 29, 2016
Research Study Confirms AirSonea’s Ability to Reliably Detect Asthma Wheezing July 25, 2016
Appendix 3Y – Change in Directors Interest Notices (x5) June 23, 2016
Allotment of Rights Issue Securities & Top 20 Shareholders June 23, 2016
RESPIRI $4.3M RIGHTS ISSUE CLOSES WITH SUCCESS June 17, 2016
RSH – Respiri Receives Strong Interest from Asia June 9, 2016
RESPIRI LIMITED – RIGHTS ISSUE May 18, 2016
Pro-rata Rights Issue May 19, 2016
RESPIRI LIMITED – RIGHTS ISSUE May 18, 2016
Respiri Limited (ASX:RSH) – Cleansing Notice May 19, 2016
Cleansing Notice – Notice under section 708A(5)(e) May 19, 2016
Appendix 3B – New Issue Announcement, Application for Quotation of Additional Securities and Agreement May 19, 2016
Respiri Announces $4.3M Fully Underwritten Rights Issue May 19, 2016
RSH Appendix 4C Third Quarter (Jan – Mar 2016) April 28, 2016
RSH – Market Update February 29, 2016
RSH – Appendix 4D Half Year Report December 31, 2015
ISN – iSonea Appoints Deloitte Touche Tohmatsu as Company Auditor November 30, 2015
ISN – 2015 Annual General Meeting – Chairman’s Address November 26, 2015
ISN – Results of iSonea 2015 Annual General Meeting November 26, 2015
ISN – Chicago University IRB Approves AirSonea Research Study November 25, 2015
ISN – iSonea to Exhibit at China Hi-Tech Fair in Shenzhen China November 5, 2015
ISN – Notice of Annual General Meeting & Explanatory Memorandum October 23, 2015

ASX ANNOUNCEMENTS

ASX ANNOUNCEMENTS

Respiri limited